Ultragenyx Pharmaceutical Class Action Notice Issued
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy RARE?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ultragenyx (NASDAQ:RARE) common stock between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to protect their rights in the lawsuit.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, thereby reducing financial barriers and encouraging broader participation from affected shareholders.
- Lawsuit Background: The lawsuit alleges that Ultragenyx made false statements regarding the efficacy of setrusumab in its Phase III Orbit and Cosmic studies, leading investors to purchase shares at artificially inflated prices, resulting in financial losses when the truth emerged.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 20.000
Low
35.00
Averages
61.65
High
120.00
Current: 20.000
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Receives FDA Clearance for UX016 Clinical Trial
- FDA Approval for Clinical Trial: Ultragenyx announced that the IND application for UX016 has been cleared by the FDA, marking a significant step towards clinical evaluation for GNE myopathy, with a Phase 1/2 study expected to begin in the second half of 2026, offering new hope for patients.
- Innovative Drug Design: UX016 is an investigational small molecule prodrug that combines sialic acid with a C16 fatty acid tail, designed to enhance biodistribution to muscle, potentially overcoming limitations of previous therapies and improving patient quality of life.
- Impact on Patient Population: GNE myopathy affects approximately 10,000 patients with no approved treatment options currently available; the clinical trial for UX016 will provide a crucial therapeutic avenue for this rare disease, potentially transforming their lives.
- External Funding Support: The program is externally funded by a patient group, reflecting the community's trust and support for Ultragenyx, which is expected to facilitate the smooth progress of the clinical study and drive the development of innovative therapies.
See More
Class Action Lawsuit Reminder Against Ultragenyx Pharmaceutical Inc.
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical for violations of securities laws, affecting shareholders from August 3, 2023, to December 26, 2025, with a deadline of April 6, 2026.
- False Statements: The complaint alleges that Ultragenyx made false and misleading statements regarding its Phase III trial performance, creating overly optimistic expectations despite failing to meet statistically significant endpoints, misleading investors throughout the class period.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in the recovery process, indicating that the company may face significant financial liabilities, which could undermine shareholder confidence and market performance.
- Legal Services: DJS Law Group specializes in securities class actions and corporate governance litigation, aiming to assist clients in recovering losses through aggressive legal advocacy, showcasing its expertise and influence in complex legal matters.
See More
Ultragenyx Pharmaceutical Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Ultragenyx Pharmaceutical for violations of securities laws, concerning securities transactions from August 3, 2023, to December 26, 2025, with a deadline to contact the firm by April 6, 2026, for participation.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its drug candidate's effects on patients with Osteogenesis Imperfecta, leading investors to have an incorrect optimistic outlook on the company's future performance, which impacted their investment decisions.
- Clinical Trial Failure: The company's Phase III ORBIT study failed to achieve a statistically significant reduction in annualized fracture rate, revealing significant errors in the company's understanding of its drug's efficacy, further exacerbating investor losses.
- Legal Consequences: As the market became aware of Ultragenyx's true situation, investors suffered losses, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for compensation, highlighting serious deficiencies in the company's transparency and compliance.
See More
Ultragenyx Pharmaceutical Class Action Lawsuit Update
- Lawsuit Timeline: Ultragenyx Pharmaceutical faces a class action lawsuit for false statements made between August 3, 2023, and December 26, 2025, with investors needing to apply as lead plaintiff by April 6, 2026, highlighting significant legal risks and potential financial losses for the company.
- Stock Price Volatility: Following the announcement on July 9, 2025, that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock plummeted over 25%, and after the December 29, 2025, announcement of further study failures, the stock fell another 42%, reflecting extreme market pessimism regarding the company's future.
- Details of Legal Allegations: The lawsuit alleges that Ultragenyx and its executives made misleading statements regarding the risks associated with Osteogenesis Imperfecta, failing to disclose critical information that severely undermined investor confidence and could impact the company's ability to raise funds.
- Role of Robbins Geller: Robbins Geller, a leading class action law firm, recovered over $916 million for investors in 2025, showcasing its strength in securities fraud cases, which may significantly influence the outcome of the Ultragenyx lawsuit.
See More
Ultragenyx Pharmaceutical Faces Class Action for Securities Fraud
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against Ultragenyx Pharmaceutical and its executives, seeking damages for investors who purchased securities between August 3, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations of Misrepresentation: The complaint alleges that throughout the class period, defendants made false or misleading statements and failed to disclose risks associated with the Phase III Orbit study on Osteogenesis Imperfecta, leading investors to have a distorted view of the company's prospects.
- Investor Action Deadline: Affected investors must request to be appointed as lead plaintiff by April 6, 2026, indicating the importance of investor initiative in legal proceedings and potentially influencing future compensation outcomes.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC specializes in securities fraud class actions and has recovered hundreds of millions for investors nationwide, underscoring its critical role in upholding market integrity and protecting investor rights.
See More
Faruqi & Faruqi Encourages Ultragenyx Investors to Reach Out
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc, specifically targeting investors who purchased or acquired securities between August 3, 2023, and December 26, 2025, reminding them of their legal rights.
- Investor Contact Information: Investors who have suffered losses are encouraged to contact Faruq & Faruqi's Securities Litigation Partner, Josh Wilson, directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Ultragenyx is April 6, 2026, urging investors to act before this date to protect their rights.
- Potential Claims Investigation: As a leading national securities law firm, Faruq & Faruqi is actively investigating potential claims against Ultragenyx, demonstrating a commitment to investor rights that may impact the company's reputation and stock price.
See More
Ultragenyx Receives FDA Clearance for UX016 Clinical Trial
- FDA Approval for Clinical Trial: Ultragenyx announced that the IND application for UX016 has been cleared by the FDA, marking a significant step towards clinical evaluation for GNE myopathy, with a Phase 1/2 study expected to begin in the second half of 2026, offering new hope for patients.
- Innovative Drug Design: UX016 is an investigational small molecule prodrug that combines sialic acid with a C16 fatty acid tail, designed to enhance biodistribution to muscle, potentially overcoming limitations of previous therapies and improving patient quality of life.
- Impact on Patient Population: GNE myopathy affects approximately 10,000 patients with no approved treatment options currently available; the clinical trial for UX016 will provide a crucial therapeutic avenue for this rare disease, potentially transforming their lives.
- External Funding Support: The program is externally funded by a patient group, reflecting the community's trust and support for Ultragenyx, which is expected to facilitate the smooth progress of the clinical study and drive the development of innovative therapies.
See More
Class Action Lawsuit Reminder Against Ultragenyx Pharmaceutical Inc.
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical for violations of securities laws, affecting shareholders from August 3, 2023, to December 26, 2025, with a deadline of April 6, 2026.
- False Statements: The complaint alleges that Ultragenyx made false and misleading statements regarding its Phase III trial performance, creating overly optimistic expectations despite failing to meet statistically significant endpoints, misleading investors throughout the class period.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in the recovery process, indicating that the company may face significant financial liabilities, which could undermine shareholder confidence and market performance.
- Legal Services: DJS Law Group specializes in securities class actions and corporate governance litigation, aiming to assist clients in recovering losses through aggressive legal advocacy, showcasing its expertise and influence in complex legal matters.
See More
Ultragenyx Pharmaceutical Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Ultragenyx Pharmaceutical for violations of securities laws, concerning securities transactions from August 3, 2023, to December 26, 2025, with a deadline to contact the firm by April 6, 2026, for participation.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its drug candidate's effects on patients with Osteogenesis Imperfecta, leading investors to have an incorrect optimistic outlook on the company's future performance, which impacted their investment decisions.
- Clinical Trial Failure: The company's Phase III ORBIT study failed to achieve a statistically significant reduction in annualized fracture rate, revealing significant errors in the company's understanding of its drug's efficacy, further exacerbating investor losses.
- Legal Consequences: As the market became aware of Ultragenyx's true situation, investors suffered losses, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for compensation, highlighting serious deficiencies in the company's transparency and compliance.
See More
Ultragenyx Pharmaceutical Class Action Lawsuit Update
- Lawsuit Timeline: Ultragenyx Pharmaceutical faces a class action lawsuit for false statements made between August 3, 2023, and December 26, 2025, with investors needing to apply as lead plaintiff by April 6, 2026, highlighting significant legal risks and potential financial losses for the company.
- Stock Price Volatility: Following the announcement on July 9, 2025, that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock plummeted over 25%, and after the December 29, 2025, announcement of further study failures, the stock fell another 42%, reflecting extreme market pessimism regarding the company's future.
- Details of Legal Allegations: The lawsuit alleges that Ultragenyx and its executives made misleading statements regarding the risks associated with Osteogenesis Imperfecta, failing to disclose critical information that severely undermined investor confidence and could impact the company's ability to raise funds.
- Role of Robbins Geller: Robbins Geller, a leading class action law firm, recovered over $916 million for investors in 2025, showcasing its strength in securities fraud cases, which may significantly influence the outcome of the Ultragenyx lawsuit.
See More
Ultragenyx Pharmaceutical Faces Class Action for Securities Fraud
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against Ultragenyx Pharmaceutical and its executives, seeking damages for investors who purchased securities between August 3, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations of Misrepresentation: The complaint alleges that throughout the class period, defendants made false or misleading statements and failed to disclose risks associated with the Phase III Orbit study on Osteogenesis Imperfecta, leading investors to have a distorted view of the company's prospects.
- Investor Action Deadline: Affected investors must request to be appointed as lead plaintiff by April 6, 2026, indicating the importance of investor initiative in legal proceedings and potentially influencing future compensation outcomes.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC specializes in securities fraud class actions and has recovered hundreds of millions for investors nationwide, underscoring its critical role in upholding market integrity and protecting investor rights.
See More
Faruqi & Faruqi Encourages Ultragenyx Investors to Reach Out
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc, specifically targeting investors who purchased or acquired securities between August 3, 2023, and December 26, 2025, reminding them of their legal rights.
- Investor Contact Information: Investors who have suffered losses are encouraged to contact Faruq & Faruqi's Securities Litigation Partner, Josh Wilson, directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Ultragenyx is April 6, 2026, urging investors to act before this date to protect their rights.
- Potential Claims Investigation: As a leading national securities law firm, Faruq & Faruqi is actively investigating potential claims against Ultragenyx, demonstrating a commitment to investor rights that may impact the company's reputation and stock price.
See More
